Glery Alvarado

[European Society of Cardiology Journals @ESC_Journals]

New in #EJPC: Beyond one-size-fits-all cardiovascular prevention.
A new review explores pathway-guided, patient-centered strategies targeting lipids, inflammation, thrombosis, and endothelial dysfunction to address residual risk and personalize treatment.
🔗 https://t.co/C9JRaubBTw

[Respirology @RespirologyAPSR]

📣 INVITED REVIEW: Asthma: From Phenotypes to Endotypes—Beyond Type 2 Inflammation
🖋️ Mario Fernando, Gregory G. King
https://t.co/u68R29QxAi
#OpenAccess

[ADA Professional Publications @ADA_Pubs]

📚 NOW AVAILABLE: Medical Management of Type 2 Diabetes
We're excited to announce the ninth edition of an essential clinical resource. Expert authors interpret the latest research on diagnosis and classification, management, and complications of type 2 diabetes.

This definitive update features all-new sections on hypoglycemia, obesity, and psychosocial care, as well as expanded discussions of:

✓ Diabetes education and behavior change strategies
✓ Nutrition therapy and physical activity recommendations
✓ Diabetic ketoacidosis and other acute complications
✓ Glycemic, cardiovascular, and renal benefits of pharmacological interventions
✓ Paradigm-changing diabetes technologies

In accordance with the latest Standards of Care in Diabetes, this text provides clinicians the knowledge and skills they need to ensure optimal care for people living with this complex condition.

📖 Read individual chapters online: https://t.co/hdQGM7c7Dj
🛒 Purchase your printed copy: https://t.co/z0vr9pvg9K
#DiabetesCare #MedicalReference #HealthcareProfessionals #DiabetesTreatment

[Rare Diseases @CheckOrphan]

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint - For More Information Visit https://t.co/ZLn8TqXs75 @bmsnews #IPF #Idiopathic_Pulmonary_Fibrosis #Rare_Diseases #Orphan_Drugs

[Marcos Gamboa @mrcsgmb84]

El índice Triglicéridos-Glucosa (TyG) se consolida como una herramienta clínica revolucionaria para valorar el riesgo aterosclerotico: simple, económica y al alcance de nuestra consulta diaria.🧵👇
@gt_rcv @Diabetes_SEMI @preventiva_SEC @SIAComunidad @gonzaeperez
@drdargaray @FaustoHerediaDr @maxima

[ObesitySEEN @ObesitySeen]

🧬 Más allá de los GLP-1: ¿qué viene después en el tratamiento farmacológico de la obesidad?
Una revisión en Pharmaceuticals mapea las nuevas dianas: amilina, CRHR2, GDF8/activina A, LEAP2…
El gran reto: perder grasa sin perder músculo 💪
https://t.co/r1PdDdytCe

[Respirology @RespirologyAPSR]

Impact of Severe COVID-19 on Interstitial Lung Disease in Autoimmune Systemic Diseases
https://t.co/A20cM5w3go

[ATS Red Journal @AJRCMB]

ATS Red Journal Editor's Choice: Current insight into the molecular mechanisms of lymphangioleiomyomatosis #LAM @atscommunity
https://t.co/ovD7735RGN

[Respirology @RespirologyAPSR]

Pulmonary Mycobacterium fortuitum Infection Associated With Achalasia Treated With Peroral Endoscopic Myotomy Alone: A Case Report
https://t.co/plqDMFOOS7

[Glery Alvarado @GleryAT]

Nobel Medicina 2026

[redGDPS Diabetes @redGDPS]

En #EASD2026 se ha presentado el ensayo SMARTEST, y el comentario de @carlos_teixi en #BlogdeMateu plantea el dilema:
💢 ¿Metformina aún como primera línea? ¿O mejor un iSGLT2? ¡Llega el ensayo

 Y nos dice al final
“Larga vida a la Reina Metformina”

https://t.co/HOtKXHnSNU

[jpedrokessner @KessnerJp]

Acute Exacerbation in Fibrotic Interstitial Lung Disease:
@ATSBlueEditor
https://t.co/gtlMioezA8

[ERS @EuroRespSoc]

In the latest ERJ Podcast, Deputy Chief Editor Don Sin interviews Marlies van Dijk (University of Groningen, Groningen, Netherlands) about her multicentre randomised crossover trial of fentanyl & morphine for persistent dyspnoea in COPD: https://t.co/nVQXj1kdZs

@ERSpublications

[Diabetologia @DiabetologiaJnl]

In our 2026 special issue: Non-pharmacological treatment of #MASLD https://t.co/JCTz94d86D

[redGDPS Diabetes @redGDPS]

En el #BlogdeMateu seguimos en #EASD2026 con lo más destacado:

💢 La Revolución de la insulina semanal

Con el comentario del Dr. Enrique Carretero Anibarro (@Enriq_Carretero)

Leer en ⤵️

https://t.co/OtYY8NOC2J

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

Re-evaluating the concept of remission in type 2 #diabetes: a call for patient-centric approaches https://t.co/74ij8PfU3x
#T2D #remission
#EASD2026

[Respirology @RespirologyAPSR]

Hot Tub Lung: Misdiagnosed Hypersensitivity Pneumonitis Revealing a Mycobacterial Aetiology—A Case Report and Literature Review
https://t.co/bZIumF4IMH

[Respirology @RespirologyAPSR]

🗨️ EDITORIAL: Pulmonary Alveolar Proteinosis: Is the Focus in Treatment Shifted From ‘Physical’ to ‘Pharmacological’?
🖋️ Yasuhiko Nishioka
https://t.co/DiWPQ5lIXS
on recent research
https://t.co/NVGmek8tOO

[ADA Professional Publications @ADA_Pubs]

Microdosing tirzepatide vials may improve GLP-1RA access, affordability, and tolerability but also presents risks of contamination, infection, and dosing errors, warranting education and precaution.

Read here ➡️ https://t.co/rITP2jLkXx

@AmDiabetesAssn @ADA_DiabetesPro

[Respirology @RespirologyAPSR]

Congenital Bronchial Atresia Mimicking Pulmonary Sequestration in the Lower Lobe: A Case Report
https://t.co/mzk9aMxCvj